In the open‐label, multicenter phase III LACEWING trial, 123 FLT3mut AML patients were randomized 2:1 to the FLT3 inhibitor gilteritinib in combination with azacitidine or simply azacitidine.105. Here, FLT3 is linked to acute myeloid leukemia.